Naoya Yamazaki
National Cancer Centre Japan(JP)National Cancer Center(US)National Cancer Center Hospital East(JP)Tokyo National Hospital(JP)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Nonmelanoma Skin Cancer Studies
Most-Cited Works
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial(2018)1,007 cited
- → The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies(2020)795 cited
- → Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments(2022)778 cited
- → Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial(2018)581 cited
- → Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial